Rising Arthritis Prevalence Fuels Expansion Of Generic Musculoskeletal Disorders Drugs Market: Powering Innovation and Expansion in the Generic Musculoskeletal Disorders Drugs Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Generic Musculoskeletal Disorders Drugs Market Through 2025?
The market size for generic drugs treating musculoskeletal disorders has seen significant growth in the past few years. The market projections show an increase from $0.06 billion in 2024 to $0.06 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.7%. This historic growth pattern is linked to factors such as the prevalence of musculoskeletal disorders, regulatory frameworks, advancements in healthcare infrastructure, enhanced patient understanding and education, as well as economic factors.

What's the Projected Size of the Global Generic Musculoskeletal Disorders Drugs Market by 2029?
Expectations are high for substantial growth in the generic musculoskeletal disorders drugs market in the coming years. Projections suggest an expansion to "$0.08 billion in 2029, at a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this predicted growth during the forecast period include increased population and aging, burgeoning markets, the rise of precision medicine and personalized treatments, healthcare reforms, and global health trends. Trends to watch in the forecast period encompass technological interventions in treatment, government schemes, and healthcare policies, a heightened focus on alternative pain management solutions, the widespread use of biosimilars, and progress in generic drug advancement.

View the full report here:
https://www.thebusinessresearchcompany.com/report/generic-musculoskeletal-disorders-drugs-global-market-report

Top Growth Drivers in the Generic Musculoskeletal Disorders Drugs Industry: What's Accelerating the Market?
The expanding incidence of arthritis is projected to drive the development of the generic musculoskeletal disorders drugs market. Arthritis, characterized by joint swelling and tenderness accompanied by symptoms of joint pain and stiffness, benefits greatly from these generic drugs, which help alleviate muscle pain and stiffness and can deal with muscle spasms in arthritis sufferers. For example, data published by Versus Arthritis, a charitable organization from the UK, in March 2022 reveals that in the UK, nearly 10 million individuals have been diagnosed with osteoarthritis, amongst which 5.4 million people have knee OA, and 3.2 million people have hip OA. In addition, around 450,000 people suffer from rheumatoid arthritis, and 190,000 people suffer from psoriatic arthritis. This adds up to more than 20 million individuals grappling with musculoskeletal ailments, leading to over 30 million prescriptions for these treatments being dispensed at a cost of about £139 million in 2022-2023. This high incidence of arthritis is thus driving the growth of the generic musculoskeletal disorders drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9433&type=smp

What Trends Will Shape the Generic Musculoskeletal Disorders Drugs Market Through 2029 and Beyond?
The growing trend of strategic alliances is becoming increasingly noticeable in the generic musculoskeletal disorders drugs market. Many firms within this market segment are entering into collaborations to bolster their stronghold. For instance, the Japan-based Mitsubishi Tanabe Pharma Corporation forged an alliance with Eli Lilly and Company, a US-based pharma firm, in July 2022. This strategic partnership seeks to enhance their respective product offerings and provide effective treatment options for conditions including diabetes. Also, in February 2022, Pfizer Inc., a pharmaceutical and biotech firm based in the US, entered a business partnership with Sweden's Alex Therapeutics, a digital therapeutics company. This collaborative arrangement is expected to provide patients with clinically-proven and personalized digital therapeutics rooted in evidence-based research.

What Are the Main Segments in the Generic Musculoskeletal Disorders Drugs Market?
The generic musculoskeletal disorders drugs market covered in this report is segmented -

1) By Treatment Type: Medication, Therapy, Surgery, Other Treatment Types
2) By Disorder Type: Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy

Subsegments:
1) By Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologics
2) By Therapy: Physical Therapy, Occupational Therapy, Chiropractic Treatment, Massage Therapy
3) By Surgery: Joint Replacement Surgery, Arthroscopy, Spinal Surgery, Fusion Surgery
4) By Other Treatment Types: Lifestyle Modifications, Alternative Therapies, Assistive Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9433&type=smp

Which Top Companies are Driving Growth in the Generic Musculoskeletal Disorders Drugs Market?
Major companies operating in the generic musculoskeletal disorders drugs market include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca plc, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Eisai Co. Ltd., Biogen Inc., Sino Biopharmaceutical Limited, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Mylan Pharmaceuticals Inc., Taisho Pharmaceutical Holdings Co. Ltd., Flexion Therapeutics Inc.

Which Regions Will Dominate the Generic Musculoskeletal Disorders Drugs Market Through 2029?
Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9433

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.